Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Christian Daniel Fankhauser; Jan Oldenburg; Peter Albers; Ferran Algaba; Carsten Bokemeyer; Joost L Boormans; Stefanie Fischer; Karim Fizazi; Hendrik Gremmels; Javier Mayor de Castro; Florian Janisch; Tim Muilwijk; Ricardo Leão; David Nicol; Nicola Nicolai; Torgrim Tandstad; M Pilar Laguna

doi:10.1016/j.eururo.2021.02.032

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Eur Urol. 2021 Jul;80(1):4-6. doi: 10.1016/j.eururo.2021.02.032. Epub 2021 Mar 12.

Authors

Christian Daniel Fankhauser¹, Jan Oldenburg², Peter Albers³, Ferran Algaba⁴, Carsten Bokemeyer⁵, Joost L Boormans⁶, Stefanie Fischer⁷, Karim Fizazi⁸, Hendrik Gremmels⁹, Javier Mayor de Castro¹⁰, Florian Janisch¹¹, Tim Muilwijk¹², Ricardo Leão¹³, David Nicol¹⁴, Nicola Nicolai¹⁵, Torgrim Tandstad¹⁶, M Pilar Laguna¹⁷

Affiliations

¹ Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. Electronic address: cdfankhauser@gmail.com.
² Department of Oncology, Oslo University Hospital, Oslo, Norway.
³ Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.
⁴ Department of Pathology, Fundacio Puigvert, Barcelona, Spain.
⁵ Department of Oncology, Hematology and Bone Marrow Transplantation with Pneumology Section, Universitätskliniken Eppendorf, Hamburg, Germany.
⁶ Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
⁷ Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
⁸ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁹ European Association of Urology Guidelines Office, Arnhem, The Netherlands.
¹⁰ Department of Urology, Hospital Gregorio Marañón, Madrid, Spain.
¹¹ Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹² Department of Urology, University Hospitals Leuven, Leuven, Belgium.
¹³ Department of Urology, Faculty of Medicine, University of Coimbra, Clinical Academic Center of Coimbra, Coimbra, Portugal.
¹⁴ Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁶ Department of Oncology, The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway.
¹⁷ Department of Urology Medipol Mega, Istanbul Medipol University, Istanbul, Turkey.

PMID: 33722419
DOI: 10.1016/j.eururo.2021.02.032

Abstract

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.

Publication types

Editorial

MeSH terms

Anticoagulants
Humans
Male
Neoplasms, Germ Cell and Embryonal* / drug therapy
Neoplasms, Second Primary*
Risk Assessment
Testicular Neoplasms* / drug therapy
Urology*
Venous Thromboembolism* / chemically induced
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants

Supplementary concepts

Testicular Germ Cell Tumor